Metrifonate: A cholinesterase inhibitor for Alzheimer's disease therapy

CNS Drug Reviews

Volumn 5, Issue 1, 1999, Pages 13-26

  Schneider, Lon S ^a,c   Giacobini, Ezio ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Clinical trial; Cognition; Dementia; Metrifonate; Organophosphates

Indexed keywords

CHOLINESTERASE INHIBITOR; METRIFONATE;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; DEMENTIA; DIARRHEA; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FLATULENCE; HUMAN; LEG CRAMP; NONHUMAN; PHARMACODYNAMICS; REVIEW; RHINITIS; TABLET FORMULATION;

EID: 0032887513     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1999.tb00083.x     Document Type: Review

References (55)

1. Abdi YA, Villen T. Pharmacokinetics of metrifonate and its rearrangement product dichlorvos in whole blood. Pharmacol Toxicol 1991;68:137-139.
2. Aldridge WN, Barnes JM. Further observations on the neurotoxicity of organophosphorus compounds. Biochem Pharmacol 1966;15:541-548.
3. Bassant MH, Jazat-Poindessous F, Lamour Y. Effects of metrifonate, a cholinesterase inhibitor, on local cerebral glucose utilization in young and aged rats. J Cereb Blood Flow Metab 1966;16:1014-1025.
4. Becker RE, Colliver J, Elble R, et al. Effects of metrifonate, a long-acting cholinesterase inhibitor in Alzheimer's disease: Report of an open trial. Drug Dev Res 1990;19:425-134.
5. Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor. for Alzheimer's disease. Alzheimer Dis Assoc Disord 1966;10:124-131.
6. Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S. Effects of metrifonate on cognitive decline in Alzheimer disease: A double-blind, placebo-controlled, 6-month study. Alzheimer Dis Assoc Disord 1998;12:54-57.
7. Becker RE, Giacobini E. Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: Clinical, pharmacological, and therapeutic aspects. Drug Dev Res 1988;17:163-195.
8. Bieber F, Meulin D, Ouvry I, et al. Clinical studies of metrifonate as a treatment for Alzheimer's disease: An overview. JNSCAG 1997;150:S59.
9. Bjorklund M, Jakala P, Schmidt B, Riekkinen M, Koivisto E, Riekkinen P, Jr. An indirect cholinesterase inhibitor, metrifonate, increases neocortical EEG arousal in rats. Neuroreport 1966;7:1097-1101.
10. Blokland A, Hinz V, Schmidt B. Effects of metrifonate and tacrine in the spatial Morris task and modified Irwin test: Evaluation of the efficacy/safety profile in rats. Drug Dev Res 1995;36:166-179.
11. Crismon ML. Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease. Pharmacotherapy 1998;18:47-54; discussion 79-82.
12. Cummings JL. Metrifonate: Overview of safety and efficacy. Pharmacotherapy 1998;18:43-46; discussion 79-82.
13. Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. [published corrections appear in Neurology 1998;51(1):332). Neurology 1998;50:1214-1221.
14. Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. [published corrections appear in Neurology 1998;51(1):332). Neurology 1998;50:1214-1221.
15. Durham WF, Gaines TB, Hayes WJ. Paralytic and related effects of certain organic phosphorus compounds. Arch Industr Health 1956;13:326-330.
16. Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology 1998;50:669-677.
17. Gaines TB. Acute toxicity of pesticides. Toxicol Appl Pharmacol 1969;14:515-534.
18. Giacobini E, Cholinesterase inhibitors do more than inhibit cholinesterase. In: Becker EGR, ed. Alzheimer Disease: From Molecular Biology to Therapy. Boston: Birkhäuser, 1996:187-204.
19. Giacobini E. From molecular structure to Alzheimer therapy. Jpn J Pharmacol 1997;74:225-241.
20. Giovannini MG, Scali C, Bartolini L, Schmidt B, Pepeu G. Effect of subchronic treatment with metrifonate and tacrine on brain cholinergic function in aged F344 rats. Eur J Pharmacol 1998;354:17-24.
21. Hallak M, Giacobini E. A comparison of the effects of two inhibitors on brain cholinesterase. Neuropharmacology 1987;26:521-530.
22. Hallak M, Giacobini E. Physostigmine, tacrine and metrifonate: The effect of multiple doses on acetylcholine metabolism in rat brain. Neuropharmacology 1989;28:199-206.
23. Heinig R, Versavel M, Breuel HP, et al. Rapid attainment of steady-state acetylcholinesterase inhibition by administration of metrifonate loading and maintenance doses once-daily in elderly volunteers. Biol Psychiatry 1997;42:94S.
24. Hinz V, Blokland A, van der Staay F. Receptors interaction profile and CNS general pharmacology of metrifonate and its transformation product dichlorvos in rodents. Drug Dev Res 1966;38:31-42.
25. Hinz V, Grewig S, Schmidt BH. Metrifonate and dichlorvos: Effects of a single oral administration on cholinesterase activity in rat brain and blood. Neurochem Res 1966;21:339-345.
26. Hinz VC, Grewig S, Schmidt BH. Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos. Neurochem Res 1966;21:331-337.
27. Holmstedt B, Nordgren I, Sandoz M, Sundwall A. Metrifonate: Summary of toxicological and pharmacological information available. Arch Toxicol 1978;41:3-29.
28. Itoh A, Nitta A, Katono Y, et al. Effects of metrifonate on memory impairment and cholinergic dysfunction in rats (published corrections appear in Eur J Pharmacol 1997;332:113). Eur J Pharmacol 1997;322:11-19.
29. Itoh A, Nitta A, Katono Y, et al. Effects of metrifonate on memory impairment and cholinergic dysfunction in rats (published corrections appear in Eur J Pharmacol 1997;332:113). Eur J Pharmacol 1997;322:11-19.
30. Johnson MK. Delayed neurotoxicity - do trichlorphon and/or dichlorvos cause delayed neuropathy in man or in test animals? Acta Pharmacol Toxicol (Copenh) 1981;49:87-98.
31. Kronforst-Collins MA, Moriearty PL, Ralph M, et al. Metrifonate treatment enhances acquisition of eyeblink conditioning in aging rabbits. Pharmacol Biochem Behav 1997;56:103-110.
32. Kronforst-Collins MA, Moriearty PL, Schmidt B, Disterhoft JF. Metrifonate improves associative learning and retention in aging rabbits. Behav Neurosci 1997;111:1031-1040.
33. Lorenz W, Henglein A, Schrader G. The new insecticide O,O-dimethyl-2,2,2-trichloro-1-hydroxyethylphosphonate. J Am Chem Soc 1955;77:2554-2556.
34. Mori F, Cuadra G, Giacobini E. Metrifonate effects on acetylcholine and biogenic amines in rat cortex. Neurochem Res 1995;20:1081-1088.
35. Mori F, Lai CC, Fusi F, Giacobini E. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroreport 1995;6:633-636.
36. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998;50:1222-1230.
37. Nordgren I, Bengtsson E, Holmstedt B, Pettersson BM. Levels of metrifonate and dichlorvos in plasma and erythrocytes during treatment of schistosomiasis with Bilarcil. Acta Pharmacol Toxicol (Copenh) 1981;49:79-86.
38. Nordgren I, Bergstrom M, Holmstedt B, Sandoz M. Transformation and action of metrifonate. Arch Toxicol 1978;41:31-41.
39. Nordgren I, Holmstedt B, Bengtsson E, Finkel Y. Plasma levels of metrifonate and dichlorvos during treatment of schistosomiasis with Bilarcil. Am J Trop Med Hyg 1980;29:426-430.
40. Ogane N, Giacobini E, Messamore E. Preferential inhibition of acetylcholinesterase molecular forms in rat brain. Neurochem Res 1992;17:489-495.
41. Ogane N, Giacobini E, Struble R. Differential inhibition of acetylcholinesterase molecular forms in normal and Alzheimer disease brain. Brain Res 1992;589:307-312.
42. Pacheco G, Palacios-Esquivel R, Moss DE. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: Selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase. J Pharmacol Exp Ther 1995;274:767-770.
43. Pettigrew LC, Bieber F, Lettieri J, et al. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease. J Clin Pharm 1998;38:236-245.
44. Raskind MA, Cyrus PA, Ruzicka BB, Gularski BI. The effetcs of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's desease patients. J Clin Psychiatry 1999;60:318-325.
45. Riekkinen M, Schmidt B, Kuitunen J, Riekkinen P, Jr. Effects of combined chronic nimodipine and acute metrifonate treatment on spatial and avoidance behavior. Eur J Pharmacol 1997;322:1-9.
46. Riekkinen P, Jr., Schmidt B, Stefanski R, Kuitunen J, Riekkinen M. Metrifonate improves spatial navigation and avoidance behavior in scopolamine-treated, medial septum-lesioned and aged rats. Eur J Pharmacol 1966;309:121-130.
47. Scali C, Giovannini MG, Bartolini L, et al. Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats. Eur J Pharmacol 1997;325:173-180.
48. Schmidt BH, Heinig R. The pharmacological basis for metrifonate's favourable tolerability in the treatment of Alzheimer's disease. Dementia Geriatr Cog Dis 1998;9:15-19.
49. Schneider LS, Farlow MR, Pogoda JM, Poirier J. Interaction of estrogen replacement therapy and Apolipoprotein E genotype status on response to cholinesterase inhibitor therapy in Alzheimer's disease. In: Iqbal BWK, Nishimura T, Takeda M, Wisniewski HM, Eds. Alzheimer's disease: Biology, diagnosis, and therapeutics. New York: John Wiley & Sons Ltd, 1997:655-659.
50. Sherman M, Ross E, Chang MT. Acute and subacute toxicity of insecticides to chicks. Toxicol Appl Pharmacol 1961;7:606-608.
51. Taylor P. Development of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease. Neurology 1998;51:S30-S35; discussion S65-S67.
52. Unni LK, Womack C, Hannant ME, Becker RE. Pharmacokinetics and pharmacodynamics of metrifonate in humans. Methods Find Exp Clin Pharmacol 1994;16:285-289.
53. van der Staay F, Hinz V, Schmidt B. Effects of metrifonate on escape and avoidance learning in young and aged rats. Behav Pharmacol 1996:56-64.
54. Watanabe H, Shirai O, Ebata N. A case report of organophosphorus insecticide (DDVP) intoxication with respiratory intensive care. Sapporo Med J 1974;43:334-337.
55. Witter R, Gaines T. Relationship between depression of brain or plasma cholinesterase and paralysis in chickens caused by certain organic phosphorus compounds. Biochem Pharmacol 1963;12:1377-1386.